COMMUNIQUÉS West-GlobeNewswire

AsymBio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates
27/05/2026
AsymBio’s Conjugation Toolbox supports customized process development across both random and site-specific conjugation technologies. For IND-enabling programs, conjugation process development timelines can be as short [...]
ViroMissile IDOV-Safe Phase 1 Data to Be Presented at the 2026 ASCO Annual Meeting
27/05/2026
IDOV-Safe demonstrates efficient intravenous delivery, manageable safety, and encouraging anti-tumor activity in heavily pretreated patients with pMMR/MSS metastatic colorectal cancer, supporting further evaluation in a [...]
TOMI Environmental Solutions Highlights Expanded Market Opportunity Following CDC-Published Hantavirus Study and Rising Global Ebola Concerns
27/05/2026
WHO-flagged Ebola outbreak and rising hantavirus exposure risks underscore growing institutional demand for scalable, hospital-grade decontamination solutions across healthcare, hospitality, transportation, and [...]
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
27/05/2026
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference [...]
Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
27/05/2026
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology RENO, Nev., May 27, 2026 (GLOBE [...]
Medicana Health Group Opens Medicana Longevity Center In Istanbul, Led By Prof. Dr. Osman Müftüoğlu
27/05/2026
The new “Longevity and Age-Related Diseases” outpatient clinic at Medicana Zincirlikuyu Hospital introduces a holistic approach focused not only on longer life, but on stronger, healthier aging Photo via FL Comms: The [...]
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026
Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant [...]
BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments
27/05/2026
BrewDog Launches Multi-Channel “Underdog” Campaign Across Retail, Bars and Digital Media — Including a Nationwide “Win a Year of Beer” Contest and Destination Match-Day Watch Parties Across the U.K. ELLON, United [...]
Invivyd to Participate in Upcoming Investor Events
27/05/2026
NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New York [...]
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
27/05/2026
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s [...]
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
27/05/2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and [...]
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
27/05/2026
Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E Virus BOSTON, May 27, 2026 [...]
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
27/05/2026
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reductions in [...]
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
27/05/2026
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability [...]
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
27/05/2026
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for [...]
Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics
27/05/2026
Company has now raised $6 million since founding to advance mRNA-based therapeutics designed to turn tumor cells into immune-activating cells SAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Reprogram Biosciences, a [...]
Satellos to Participate in Upcoming Investor Conferences
27/05/2026
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat [...]
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
27/05/2026
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, [...]
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
27/05/2026
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: [...]

Pages